Efficacy and Incidence of Adverse Reactions of Hemodialysis Combined with Roxallistat in the Treatment of Chronic Renal Failure Complicated with Severe Anemia
Objective To investigate the efficacy and incidence of adverse reactions of hemodialysis combined with Roxallistat in the treatment of chronic renal failure complicated with severe anemia.Methods Seventy patients with chronic renal failure complicated with severe anemia admitted to Pizhou People's Hospital of Jiangsu Province from January 2022 to October 2023 were randomly selected as the study subjects.They were divided into control group and study group by coin tossing method,with thirty-five cases in each group.Both groups were treated with continuous he-modialysis.On this basis,the control group was treated with recombinant human erythropoietin injection.The study group was treated with Rosallistat capsules.The therapeutic effects of the two groups were analyzed and compared.Results Before treatment,there was no statistically significant difference in hematocrit and hemoglobin concentration between the two groups(both P>0.05);after treatment,the hematocrit and hemoglobin concentrations of both groups were improved,and the hematocrit and hemoglobin concentrations of the study group were higher than those of the control group,the differences were statistically significant(both P<0.05).The incidence of adverse reactions in study group(0)was lower than that in control group(17.14%),and the difference was statistically significant(x2=4.557 P=0.033).The total effective rate of treatment in the study group(91.43%)was higher than that of the control group(71.43%),the difference was statistically significant(x2=4.629,P=0.031).Conclusion Patients with chronic renal fail-ure actively use Rosallistat capsule for continuous hemodialysis treatment,which has higher safety and effectiveness,can reduce the degree of anemia in patients,and effectively reduce the occurrence of adverse reactions.
NETL
NSTL
万方数据
